PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000849904.09812.c6 |
| _version_ | 1827332192138690560 |
|---|---|
| author | E. Jabbour G. Martinelli M. Vignetti H. Kantarjian D. Gomez-Almaguer Y. Minami H. Dombret M. Hennessy A. Vorog B. Wang J.-M. Ribera |
| author_facet | E. Jabbour G. Martinelli M. Vignetti H. Kantarjian D. Gomez-Almaguer Y. Minami H. Dombret M. Hennessy A. Vorog B. Wang J.-M. Ribera |
| author_sort | E. Jabbour |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:55:16Z |
| format | Article |
| id | doaj.art-bc110a76a6e043959ad63ad1c6bb02da |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:55:16Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-bc110a76a6e043959ad63ad1c6bb02da2024-03-03T04:28:09ZengWileyHemaSphere2572-92412022-06-0161643164410.1097/01.HS9.0000849904.09812.c6202206003-01643PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDYE. Jabbour0G. Martinelli1M. Vignetti2H. Kantarjian3D. Gomez-Almaguer4Y. Minami5H. Dombret6M. Hennessy7A. Vorog8B. Wang9J.-M. Ribera101 The University of Texas, MD Anderson Cancer Center, Houston, TX, United States of America2 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”- IRST S.r.l, Meldola3 GIMEMA Research Foundation, Rome, Italy4 The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America5 Hospital Universitario, UANL, Monterrey, Nuevo Leon, Mexico6 National Cancer Center Hospital East, Kashiwa, Japan7 Institut de Recherche Saint-Louis, Université de Paris, Hôpital Sain-Louis, Paris, France8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America9 Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spainhttp://journals.lww.com/10.1097/01.HS9.0000849904.09812.c6 |
| spellingShingle | E. Jabbour G. Martinelli M. Vignetti H. Kantarjian D. Gomez-Almaguer Y. Minami H. Dombret M. Hennessy A. Vorog B. Wang J.-M. Ribera PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY HemaSphere |
| title | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_full | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_fullStr | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_full_unstemmed | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_short | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_sort | pb1762 ponatinib versus imatinib with reduced intensity chemotherapy in patients with newly diagnosed philadelphia chromosome positive ph acute lymphoblastic leukemia all phallcon study |
| url | http://journals.lww.com/10.1097/01.HS9.0000849904.09812.c6 |
| work_keys_str_mv | AT ejabbour pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT gmartinelli pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT mvignetti pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT hkantarjian pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT dgomezalmaguer pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT yminami pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT hdombret pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT mhennessy pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT avorog pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT bwang pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT jmribera pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy |